Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

November 3, 2011

 

 

IRIDEX CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   0-27598   77-0210467

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

1212 Terra Bella Avenue

Mountain View, California 94043

(Address of principal executive offices, including zip code)

(650) 940-4700

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 2.02. Results of Operations and Financial Condition.

On November 3, 2011, IRIDEX Corporation issued a press release discussing its financial results for its third fiscal quarter of 2011, which ended October 1, 2011. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

  

Description

99.1    Press Release dated November 3, 2011.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    IRIDEX CORPORATION

By:

 

/s/ DOMINIK BECK

 

Dominik Beck

President and Chief Executive Officer

Date: November 3, 2011


EXHIBIT INDEX

 

Exhibit No.

  

Description

99.1    Press Release dated November 3, 2011.
Press Release

Exhibit 99.1

 

FOR IMMEDIATE RELEASE    LOGO

IRIDEX Reports 2011 Third Quarter and Nine-Month Results

Mountain View, Calif. – November 3, 2011…IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended October 1, 2011.

 

   

Revenues were $10.8 million, gross margins were 45.4% and operating expenses were $4.4 million for the third quarter of 2011 compared to guidance of $10 million, 45%, and $4.5 million, respectively.

 

   

Direct ophthalmology sales grew 3% in the third quarter of 2011 and 7% in the nine months of 2011. In Q3 2010, the Company benefited from an unusually large US Army order for $0.5 million. Excluding this item, direct ophthalmology sales grew 11% for the third quarter and 9% for the nine months of 2011.

 

   

For the third quarter of 2011, earnings were $0.3 million or $0.03 per diluted share, compared to $0.9 million or $0.09 per diluted share reported in the third quarter of 2010.

 

   

For the first nine months of 2011, earnings were $1.8 million or $0.18 per diluted share, compared to $2.2 million or $0.22 per diluted share reported in the first nine months of 2010. Total sales increased to $32.8 million, up 4% from $31.5 million.

“Third quarter results exceeded guidance for all categories: revenue, gross margin and operating expenses. We were especially pleased to see our core ophthalmology business grow 3% in spite of the macroeconomic uncertainties in the US and Europe and the impact these uncertainties typically have on capital expenditures,” said newly appointed President and CEO Dominik Beck. “Our largest trade show, the Annual Meeting of the American Academy of Ophthalmology, was in October and we were pleased with the business activity at the Academy.”

“Since taking the CEO role several weeks ago, I have been encouraged and impressed with the many areas of opportunity that exist for the Company, and I strongly believe I have joined IRIDEX at the right time. Having successfully completed its turnaround, the business is again growing and I believe I can accelerate that growth in 2012 and beyond and increase shareholder value through instituting a more commercial focus and driving new market-facing initiatives,” continued Dr. Beck. “IRIDEX is known as a major contributor to the successful laser therapeutic treatment of Retina and Glaucoma diseases and we will focus on increasing our footprint within these diseases.”

Guidance for fourth quarter of fiscal 2011: revenue of $11.3 million to $11.5 million, gross margin of 47% to 50% and operating expenses of $4.9 million to $5.1 million.

During the quarter, the Company continued to execute its limited share repurchase program and purchased approximately 33,000 shares at an average price of $3.66.


Q3 2011 Business Highlights

 

   

Dominik Beck was named President and Chief Executive Officer and a member of the IRIDEX Board of Directors. Dr. Beck replaced Theodore A. Boutacoff, a co-founder of IRIDEX who became Chief Technology Officer.

 

   

The Company expanded its product offering by introducing an optional MicroPulse module in the Company’s IQ532 (green) laser system and now provides a complete portfolio of infrared, yellow and green laser systems which can deliver MicroPulse laser treatments.

 

   

The Company introduced the new XP Module—a high power factory installed option for the IRIDEX IQ 532 green laser system. This is a multifunctional device that can be utilized by both ear, nose and throat (ENT) surgeons and ophthalmologists, expanding overall utilization and making a laser investment more attractive.

 

   

The Company exclusively licensed the rights to all of the intellectual property of Ocunetics, Inc., a privately held company. Ocunetics develops procedure-enabling medical devices that are intended to increase surgeons’ efficiency, while improving clinical predictability for ophthalmic surgeries.

Conference Call

IRIDEX management will conduct a conference call later today, Thursday, November 3, 2011 at 5:00 p.m. Eastern Time. Interested parties may access the live conference call via telephone by dialing (888) 561-1799 (U.S.) or (480) 629-9822 (International) and quoting Conference ID 4484068, or by visiting the Company’s website at www.iridex.com. A telephone replay will be available beginning on Thursday, November 3, 2011 through Thursday, November 10, 2011 by dialing (800) 406-7325 (U.S.) or (303) 590-3030 (International) and entering Access Code 4484068. In addition, later today an archived version of the webcast will be available on the Company’s website at www.iridex.com.

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company’s website at http://www.iridex.com.


Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the Company’s and its new Chief Executive Officer’s ability to accelerate the and continue to grow the Company’s business, increase shareholder value and expand the Company’s footprint in the areas of Retina and Glaucoma diseases, and the Company’s projected fourth quarter of fiscal 2011 financial results. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 1, 2011 and our Quarterly Reports on Form 10-Q for the quarters ended April 2, 2011, July 2, 2011 and October 1, 2011, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

 

Company Contact:      Investor Relations Contact:
Jim Mackaness      Matt Clawson
Chief Financial Officer      Allen & Caron
650-940-4700      949-474-4300
     matt@allencaron.com

TABLES FOLLOW


IRIDEX Corporation

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(unaudited)

 

     Three Months Ended      Nine Months Ended  
     October 1,     October 2,      October 1,     October 2,  
     2011     2010      2011     2010  

Revenues

   $ 10,793      $ 10,818       $ 32,803      $ 31,466   

Cost of revenues

     5,892        5,569         17,787        16,456   
  

 

 

   

 

 

    

 

 

   

 

 

 

Gross profit

     4,901        5,249         15,016        15,010   

Operating expenses:

         

Research and development

     894        920         2,768        2,913   

Sales and marketing

     2,222        2,319         7,058        6,984   

General and administrative

     1,269        1,125         3,627        3,490   
  

 

 

   

 

 

    

 

 

   

 

 

 

Total operating expenses

     4,385        4,364         13,453        13,387   
  

 

 

   

 

 

    

 

 

   

 

 

 

Income from operations

     516        885         1,563        1,623   

Legal settlement

     0        0         800        800   

Interest and other income (expense), net

     (131     63         (232     (49
  

 

 

   

 

 

    

 

 

   

 

 

 

Income before income taxes

     385        948         2,131        2,374   

Provision for income taxes

     36        38         307        165   
  

 

 

   

 

 

    

 

 

   

 

 

 

Net income

   $ 349      $ 910       $ 1,824      $ 2,209   
  

 

 

   

 

 

    

 

 

   

 

 

 

Net income per share – basic

   $ 0.04      $ 0.10       $ 0.20      $ 0.25   
  

 

 

   

 

 

    

 

 

   

 

 

 

Net income per share – diluted

   $ 0.03      $ 0.09       $ 0.18      $ 0.22   
  

 

 

   

 

 

    

 

 

   

 

 

 

Shares used in computing net income per share – basic

     8,965        8,974         8,963        8,930   
  

 

 

   

 

 

    

 

 

   

 

 

 

Shares used in computing net income per share – diluted

     10,253        10,148         10,233        10,112   
  

 

 

   

 

 

    

 

 

   

 

 

 


IRIDEX Corporation

Condensed Consolidated Balance Sheets

(In thousands)

(unaudited)

 

     October 1,     January 1,  
     2011     2011  
     (unaudited)        
Assets     

Current Assets:

    

Cash and cash equivalents

   $ 9,535      $ 9,014   

Accounts receivable, net

     7,738        7,526   

Inventories, net

     10,176        9,212   

Prepaids and other current assets

     571        620   
  

 

 

   

 

 

 

Total current assets

     28,020        26,372   

Property and equipment, net

     316        360   

Other long-term assets

     225        218   

Other intangible assets, net

     1,772        1,797   

Goodwill

     533        473   
  

 

 

   

 

 

 

Total assets

   $ 30,866      $ 29,220   
  

 

 

   

 

 

 
Liabilities and Stockholders’ Equity     

Current Liabilities:

    

Accounts payable

   $ 2,222      $ 1,981   

Accrued compensation

     1,694        2,304   

Accrued expenses

     1,657        1,822   

Accrued warranty

     802        956   

Deferred revenue

     2,132        2,134   
  

 

 

   

 

 

 

Total current liabilities

     8,507        9,197   

Long Term Liabilities:

    

Other long-term liabilities

     776        596   
  

 

 

   

 

 

 

Total liabilities

     9,283        9,793   

Stockholders’ Equity:

    

Convertible preferred stock

     5        5   

Common Stock

     92        89   

Additional paid-in capital

     41,861        41,168   

Accumulated other comprehensive loss

     (48     (205

Treasury stock, at cost

     (951     (430

Accumulated deficit

     (19,376     (21,200
  

 

 

   

 

 

 

Total stockholders’ equity

     21,583        19,427   
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 30,866      $ 29,220